OmniAb, Inc.

OmniAb, Inc., an antibody discovery company spun out of Ligand Pharmaceuticals, went public through a merger with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. The business combination was announced in March 2022 and subsequently closed, with OmniAb beginning to trade on Nasdaq under the ticker OABI as a standalone biotech focused on transgenic-animal-based antibody generation platforms. The deal falls within the biotech and pharmaceutical sector, reflecting continued SPAC interest in drug-discovery infrastructure plays during that period. The transaction is now listed as closed in SPAC tracking databases. For full deal terms, pipeline milestones, and comparable biotech SPAC data, sign up for complete access on SpacDesk.

SPAC Counterparty (1)